Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-1.1%
5Y CAGR+29.7%
Year-over-Year Change
Research and development spending
3Y CAGR
-1.1%/yr
Annual compound
5Y CAGR
+29.7%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
3.7x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $90.40M | -13.1% |
| 2024 | $104.08M | -18.8% |
| 2023 | $128.19M | +37.2% |
| 2022 | $93.45M | +112.2% |
| 2021 | $44.04M | +79.1% |
| 2020 | $24.59M | +106.7% |
| 2019 | $11.90M | - |